Rheumatoid Arthritis Blood Tests: RF, Anti-CCP & ESR Explained

What Is Rheumatoid Arthritis?

Rheumatoid arthritis (RA) is a chronic autoimmune condition that causes inflammation of the joints. Unlike osteoarthritis (which results from wear and tear), RA occurs when the immune system mistakenly attacks the synovial membrane lining the joints. This leads to pain, swelling, stiffness, and eventually joint destruction if not treated promptly.

RA affects approximately 1% of the UK population and is two to three times more common in women. Early diagnosis and treatment are critical — NICE recommends that anyone with suspected RA be referred urgently to a rheumatologist within 3 weeks of presentation. Blood tests play a central role in both diagnosis and ongoing monitoring.

Rheumatoid Factor (RF)

Rheumatoid factor is an autoantibody (usually IgM class) directed against the Fc portion of IgG antibodies. A positive RF supports the diagnosis of RA, but it is not definitive on its own:

• Sensitivity: approximately 60–70% of RA patients are RF-positive.
• Specificity: RF can also be positive in other autoimmune conditions (Sjögren’s syndrome, SLE), chronic infections (hepatitis C), and even in 5–10% of healthy people, particularly older adults.
• Prognostic value: high RF titres are associated with more severe disease, joint erosion, and extra-articular manifestations.

Anti-CCP Antibodies (Anti-Cyclic Citrullinated Peptide)

Anti-CCP antibodies are directed against citrullinated proteins, which are produced during inflammation. This test is more specific for RA than RF:

• Sensitivity: approximately 60–75%.
• Specificity: approximately 95–98% — significantly higher than RF.
• Early detection: anti-CCP antibodies can be present in the blood up to 10 years before clinical symptoms develop.
• Prognostic value: a positive anti-CCP is associated with more aggressive, erosive disease.

Patients who are positive for both RF and anti-CCP are described as seropositive RA, while those negative for both markers have seronegative RA. Seronegative RA is still a valid diagnosis and can be equally severe, but diagnosis relies more heavily on clinical examination and imaging.

ESR (Erythrocyte Sedimentation Rate)

The ESR measures how quickly red blood cells settle to the bottom of a test tube over one hour. A faster rate indicates higher levels of inflammation in the body. The normal range varies with age and sex:

• Men: up to age/2 mm/hr
• Women: up to (age + 10)/2 mm/hr

ESR is a non-specific marker — it rises in many inflammatory, infectious, and malignant conditions. In RA, it is primarily used to monitor disease activity and response to treatment rather than for diagnosis.

CRP (C-Reactive Protein)

CRP is a protein produced by the liver in response to inflammation. It rises and falls more rapidly than ESR, making it a more responsive marker of acute inflammation. In RA, CRP is used alongside ESR to calculate the Disease Activity Score (DAS28), which guides treatment decisions. A CRP above 5 mg/L is generally considered elevated, though many RA patients have levels significantly higher during active flares.

Additional Diagnostic Tests

Beyond the core RA blood tests, your rheumatologist may request:

• Full blood count (FBC) — anaemia of chronic disease is common in RA. Platelet counts may be elevated during active inflammation.
• Liver function tests (LFTs) — baseline before starting methotrexate or other hepatotoxic DMARDs.
• Renal function (U&Es) — baseline and ongoing monitoring, particularly with NSAIDs or certain biologics.
• ANA (antinuclear antibodies) — may be requested to exclude SLE if the presentation is atypical.

DMARD Monitoring

Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of RA treatment. Methotrexate is the most commonly used first-line DMARD in the UK. All DMARDs require regular blood test monitoring to detect potential side effects early:

• Methotrexate: FBC, LFTs, and U&Es every 2 weeks until the dose is stable, then monthly for 6 months, then every 2–3 months. Watch for bone marrow suppression and liver toxicity.
• Sulfasalazine: FBC and LFTs monthly for the first 3 months, then every 3 months.
• Leflunomide: FBC, LFTs, and blood pressure. Monthly for the first 6 months, then every 2 months.
• Hydroxychloroquine: baseline eye examination recommended; blood monitoring is minimal.

Biologic therapies (such as adalimumab, etanercept, or rituximab) also require baseline and periodic blood tests, including screening for hepatitis B and C and tuberculosis before starting treatment.

Getting Tested at Home

If you are experiencing joint pain, stiffness, and swelling — particularly in the small joints of the hands and feet — getting blood tests done quickly is important. A mobile phlebotomist can take your blood at home for RF, anti-CCP, ESR, CRP, and a full blood count. For patients already on DMARDs, home blood tests are a convenient way to keep up with regular monitoring without needing to visit the hospital. Explore our home blood test services for more information.